SCHEMBL7555779

SCHEMBL7555779

CCOC(Cc1ccc(CCCN2c3ccccc3COc3ccccc32)cc1)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.68
PPARA Q07869 14/20 0.68
PPARD Q03181 4/20 0.45
SMPD1 P17405 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7528971 0.90 PPARG (0.55) PPARGPPARAPPARDSMPD1
SCHEMBL7536092 0.90 PPARG (0.55) PPARGPPARAPPARDSMPD1
SCHEMBL7536852 0.90 PPARG (0.84) PPARGPPARAPPARD
SCHEMBL7526673 0.87 PPARG (0.79) PPARGPPARAPPARD
SCHEMBL7533363 0.86 PPARG (0.73) PPARGPPARAPPARD
SCHEMBL7530063 0.85 PPARG (0.68) PPARGPPARAPPARD
SCHEMBL7535724 0.82 PPARG (0.62) PPARGPPARAPPARD
SCHEMBL7527048 0.81 PPARA (0.74) PPARGPPARAPPARD
SCHEMBL7528289 0.80 PPARG (0.69) PPARGPPARAPPARD
SCHEMBL7529012 0.80 PPARG (0.70) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-15 US claimed
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-01 US claimed
EP-1123279-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023425-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6468996-B1 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. NOVO NORDISK A/S (DK) 2002-10-22 US disclosed
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-15 US disclosed
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators JEPPESEN LONE (DK) 2002-08-01 US disclosed
EP-1123279-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023425-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103188-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PPARD 3/4885
US-20020111344-A1 Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators PPARG, PPARA, PPARD PPARG 1/4885PPARA 2/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.